Alveolar rhabdomyosarcoma (ARMS) comprises a rare highly malignant tumor presumed to be associated with skeletal muscle lineage in children. The hallmark of the majority of ARMS is a chromosomal translocation that generates the PAX3-FOXO1 fusion protein, which is an oncogenic transcription factor responsible for the development of the malignant phenotype of this tumor. ARMS cells are dependent to the oncogenic activity of PAX3-FOXO1 and its expression status in ARMS tumors correlates with worst patient outcome, suggesting that blocking this activity of PAX3-FOXO1 may be an attractive therapeutic strategy against this fusion-positive disease. In this study, we screened small-molecule chemical libraries for inhibitors of PAX3-FOXO1 transcriptional activity using a cell-based readout system. We These data reveal that thapsigargin-induced activation of AKT is an effective mechanism to inhibit PAX3-FOXO1 and a potential agent for targeted therapy against ARMS.
Introduction
Alveolar rhabdomyosarcoma (ARMS) is an aggressive form of soft tissue pediatric sarcoma and exhibits a poor prognosis (1) . The overall 5-year survival rate for ARMS patients is ~ 50% (2) .
Despite modern multimodal treatment approaches, the outcome for ARMS patients remains poor. This highlights the need for new therapeutic strategies to improve ARMS patients' outcome.
The majority of ARMS is characterized by a specific chromosomal translocation t(2;13) that leads to the expression of the novel chimeric transcription factor PAX3-FOXO1. The PAX3-FOXO1 protein contains the DNA binding portions of PAX3 fused to the transactivation domain of FOXO1 (3) and acts as a potent transcriptional activator (4) . Its transcriptional activity influences the expression of genes that affect cell growth, motility and apoptosis (5) , and forced expression of PAX3-FOXO1 alone can induce oncogenic transformation (6) . However, PAX3-FOXO1 needs additional genetic lesions to give rise to ARMS (7) (8) (9) , which is also supported by mouse models of ARMS (10) . The oncogenic role of PAX3-FOXO1, which is believed to be attributed by its transcriptional activity (5, 11) , is necessary for the maintenance of the transformed phenotype (12) (13) (14) . Besides the oncogenic role of PAX3-FOXO1 in ARMS pathogenesis, its prognostic significance has also been acknowledged in patients with this fusion-positive disease where PAX3-FOXO1-positive tumors are associated with an aggressive phenotype and significantly worse prognosis (15) (16) (17) . Therefore, these evidences suggest that the inhibition of PAX3-FOXO1 activity may provide an effective treatment strategy against fusion-positive ARMS. Indeed, a variety of approaches have been taken to inhibit PAX3-FOXO1 (12, (18) (19) (20) , however, thus far no pharmaceuticals have been developed against this fusion oncoprotein.
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Author Manuscript Published OnlineFirst on October 9, 2013; DOI: 10.1158/1535-7163. This study described the development of a screening approach to identify small-molecule inhibitors of PAX3-FOXO1 transcriptional activity. To this end, a PAX3-FOXO1-responsive luciferase reporter was used as a primary readout followed by several secondary assays in evaluating PAX3-FOXO1 activity in ARMS cells to evaluate 3,280 pharmacological compounds.
The most active candidate of PAX3-FOXO1 inhibitor identified in this screen was thapsigargin (TG) that acts as a potent inhibitor of Sarco/Endoplasmic Reticulum Ca 2+ -ATPases (SERCA) (21) . Further characterization of this compound revealed that activation of AKT by TG inhibited the transcriptional activity of PAX3-FOXO1 via phosphorylation and subsequently promoted proteosomal degradation. This TG-induced AKT activation was apparently due to the increased intracellular Ca 2+ levels. Moreover, TG inhibits the malignant characteristics of ARMS cells in vitro and blocks ARMS tumor growth in vivo. These findings offer a novel preclinical rationale for a TG-based approach to target PAX3-FOXO1 activity as a therapeutic strategy against ARMS.
Materials and Methods

Cells and cell culture
Mouse ARMS cell lines U20497T and U20325 were previously described (22, 23) . Human ARMS cell lines Rh7, Rh28, Rh30 and Rh41 were provided by Dr. Peter. J Houghton (Nationwide Children's Hospital, OH). C2C12, RD, 293A and Phoenix-Ampho cell lines were authenticated as described previously (23, 24) . U20497T-PRSLuc and U20325-PRSLuc cells expressing the PAX3-FOXO1-responsive reporter luciferase (6XPRS-Luc) generated through lentivirus transduction were described previously (23 (20% FBS). Additional details, including reagents, inhibitors, plasmids, antibodies, and virus production and transduction, are described in Supplementary Materials and Methods.
Screening of small molecule libraries
To screen for inhibitors of the PAX3-FOXO1 transcriptional activity, a total of 3,280 compounds were used. U20325-PRSLuc cells were used as a screening readout to identify compounds that decreased reporter luciferase activity. Briefly, the above cells were incubated with library compounds for 24 hours followed by luciferase activity assay. The criterion used to define hits in the primary screen was the decreased luciferase activity greater than 70% of solvent DMSO control. Compounds fulfilling the above criterion were subsequently subjected to a secondary screen to evaluate compounds that decreased luciferase activity in a dose-response manner but had no effect on cell viability. Nine compounds were selected based on dose-dependent decreased luciferase activity, while maintaining greater than 80% cell viability. Details of small molecule libraries and screening of primary and secondary assays are provided in Supplementary Materials and Methods.
Luciferase assay, immunoblot and RT-PCR analysis
Luciferase assay and analysis of immunoblot and RT-PCR were done as described in Supplementary Materials and Methods.
Measurement of intracellular calcium
Intracellular free calcium in ARMS cells was determined using Fluo-4 Direct Calcium Assay kit (Invitrogen) according to the Manufacturer's protocol. In brief, 2x10 4 ChIP, cell proliferation, clonogenic and soft-agar colony formation assays.
These assays were performed as described previously (23, 24) . Additional details were described in Supplementary Material and Methods.
Apoptosis-DNA ladder formation Assay
Rh28 and Rh30 cells (5x10 6 ) were seeded in 10 cm 2 dishes and incubated overnight. Cells were then treated with TG or vehicle control. After 4 days treatment, both attached and floated cells were collected, washed and lysed by cell lysis buffer (25) . Cell extracts were clarified by centrifuge and SDS was added to the extracts (1% final). The extracts were then treated with RNase A (5µg/µl) for 2 hours at 56°C followed by proteinase K (2.5 µg/µl) for 2 hours at 37°C.
Subsequently, DNA was extracted by with a mixture of phenol, chloroform isoamyl alcohol followed by ethanol precipitation and resolved on a 2% agarose gel and documented.
Invasion Assay
This assay was performed according to 
Xenograft experiments
All animal studies were conducted in accordance with the Guidance for the Care 
Immunohistochemistry analysis
Briefly, formalin fixed dissected tumors were embedded in paraffin for immunohistochemistry analysis. Paraffin sections were the stained with hematoxylin-eosin (H&E) or subjected to immunohistochemical staining for Ki-67 and activated caspase 3. Stained slides were counterstained with hematoxylin, mounted, and images were captured. Additional details are described in Supplementary Materials and Methods.
Statistical analysis
Unpaired two-tailed student's t test analyses were performed to ascertain statistical significance and a P value less than 0.05 was considered statistically significant.
Results
Screening of small-molecule libraries identify thapsigargin as an inhibitor of PAX3-
FOXO1
This study was aimed to identify compounds that inhibit PAX3-FOXO1 activity in ARMS cells. A screening was conducted of small-molecule libraries that consisted of 3,280 compounds to identify those that suppress PAX3-FOXO1 transcriptional activity. (Fig. 2D) . Finally, to verify that the inhibition of PAX3-FOXO1 activity by TG was due to AKT activation, luciferase activity in Rh30-PRSLuc cells was determined following the expression of a constitutive active form of AKT (myrAKT-HA). Indeed, constitutive active AKT retrovirus but not control retrovirus decreases luciferase activity (Fig.   2E ). Together, the results suggest that TG inhibited the transcriptional activity of PAX3-FOXO1 via phosphorylation due to an increase in the levels of activated AKT.
Thapsigargin-induced Ca
2+ levels correlate with AKT activation inhibited PAX3-FOXO1 transcriptional activity followed by its proteasomal degradation
Thapsigargin disrupts the endoplasmic reticulum (ER) Ca 2+ store and elevates cytosolic Ca 2+ levels, which affects downstream signaling pathways involved in multiple cellular responses (21, 32, 33) . Since TG activated AKT inhibits PAX3-FOXO1 transcriptional activity in ARMS cells (Fig. 2) , it was possible that the activation of AKT and subsequent inhibition of PAX3-FOXO1 activity was caused by TG-induced rise of cytosolic Ca 2+ levels in these cells. Indeed, TG 3B ) and a decrease in PAX3-FOXO1-responsive reporter luciferase activity in Rh30-PRSLuc cells (Fig. 3C) . These results suggest that the effect of TG on AKT activation and PAX3-FOXO1
transcriptional activity is at least partially due to its effect on intracellular calcium levels.
Although TG-induced AKT activation correlated with increased levels of phosphorylated PAX3-FOXO1 in ARMS cells ( Fig. 2A) , TG also decreased PAX3-FOXO1 protein levels in these cells (Fig. 1E) . It was postulated that the AKT activation mediated increase in phosphorylated PAX3-FOXO1 will subsequently be declined in ARMS cells treated with TG. Indeed, an increased levels of phosphorylated PAX3-FOXO1 followed by decreased protein levels was observed in TG-treated RH30 cells (Fig. 3D) . (Fig.   4B) . Moreover, the analysis of chromatin used for ChIP showed that the expression of PAX3-FOXO1-HA was not affected by TG, suggesting that the deficiency of PAX3-FOXO1 chromatin occupancy on MYOD was not due to the decreased levels of PAX3-FOXO1 protein in TGtreated cells. The quantitative PCR analysis of ChIP DNA also showed that PAX3-FOXO1 chromatin occupancy on MYOD and second intron of IGF1R, which is a target bound and directly regulated by PAX3-FOXO1 (29), was severely impaired in TG-treated these cells (Fig.   4C ). Together, the data imply that TG eradicates PAX3-FOXO1 binding to its targets resulting in the suppression of PAX3-FOXO1-mediated gene transcription in ARMS cells.
Thapsigargin inhibits ARMS cell tumorigenic potential and induces apoptosis in vitro
Studies have indicated that the inhibition of either PAX3-FOXO1 activity or expression blocks the growth and induces apoptosis of ARMS cells (14, 18, 20, 31) . Since TG suppresses PAX3-FOXO1 activity and subsequently its abolition in ARMS cells ( Fig. 2 and 3) , the effect of TG on ARMS cell growth was examined. The results showed that TG severely impaired the growth of a panel of ARMS cell lines (Fig. 5A) . The effectiveness of TG on the survival ability of these ARMS cells to grow into colonies was also examined and the data showed a severe decrease in number of colonies in TG-treated cells (Fig. 5B) . These results provoked the exploration of apoptosis in TG-treated ARMS cells by examining the levels of cleaved caspase 3 and PARP, which are biomarkers of apoptosis. Indeed, an increased level of these apoptotic markers were observed in Rh28 and Rh30 cells treated with TG (Fig. 5C) . Moreover, TG-induced apoptosis in Fig. S4 ).
Studies have also implicated that PAX3-FOXO1 expression in ARMS confers an aggressive phenotype in vivo such as tumorigenic and metastatic potential (5, 38) . The anchorage-independent growth of tumor cells in vitro is generally assumed to be closely related to the above in vivo events. Therefore, the effect of TG on the ability of ARMS cells to exhibit anchorage-independent cell growth was evaluated in Rh30 and U20325 cells by examining colony-forming capacity in semi-solid soft agar media. The results showed that TG inhibited the growth of these cells as evidenced by the decreased number of colonies (Fig. 5D) . Additionally, the effect of TG was evaluated on invasive behavior of ARMS cells, one of the hallmarks of the metastatic potential. This was performed by treating Rh30 and U20325 cells with TG and measuring the invasiveness with a Matrigel invasion assay. The data showed that TG also inhibited these cells invasion through Matrigel (Fig. 5E) . Together, these in vitro results demonstrate that TG is able to block ARMS cell growth, survival, metastatic ability and induce apoptosis.
Thapsigargin inhibits the growth of human ARMS xenografts in vivo
Finally, the in vivo effect of TG on tumor growth was evaluated using an Rh28 ARMS xenograft (Fig. 6A) . However, the mice that were treated with TG either 0.1 or 0.15 mg/kg showed a significant reduced tumor growth when measuring the tumor volume (Fig. 6B) . To further characterize the effect of TG on tumor growth in vivo, the resected tumors from both TGtreated and control mice were sectioned and stained with H&E or used for immunohistochemical analysis. As shown in Fig. 6C , H&E staining of tumor sections showed less viable round cell morphology in TG-treated mice (Fig. 6C) . Moreover, tumors sections stained with antibody against proliferation marker Ki-67 and apoptosis-inducing activated caspase 3 evidently showed the decreased Ki-67 but increased activated caspase 3 positive-cells in TG-treated mice.
Together, the results display in vivo inhibition of tumor-cell proliferation and concomitant increased apoptosis in ARMS tumor model following TG treatment.
Discussion
In this study, a cell-based screening system was used to identify small-molecule inhibitors of 
identifying TG as a first-in-class inhibitor of PAX3-FOXO1 suppressing ARMS cell growth and malignant phenotypes. Moreover, this system can be expanded in evaluating additional smallmolecule libraries to identify potential inhibitors of PAX3-FOXO1.
The screening-identified TG was originally isolated from plant Thapsia garganica L. (Linnaeus) (39) . Although TG is most widely used inhibitor of SERCA to study intracellular Ca 2+ signaling (21) , its action is also associated with the activation of apoptosis in cells (33) . This apoptotic aspect of TG has recently exploited to develop a TG-derived prodrug for cancer therapy (40) . 
